Dexcom Inc. Stock
Dexcom Inc. Stock
Dexcom Inc. dominated the market today, gaining €7.60 (11.730%).
With 54 Buy predictions and 2 Sell predictions Dexcom Inc. is one of the favorites of our community.
As a result the target price of 74 € shows a slightly positive potential of 2.21% compared to the current price of 72.4 € for Dexcom Inc..
For the coming years our community has positive and negative things to say abot the Dexcom Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Dexcom Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dexcom Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dexcom Inc. | 11.730% | 14.921% | 22.712% | 2.289% | 26.308% | -36.099% | -33.395% |
| Idexx Laboratories Inc. | 0.470% | 1.232% | 5.232% | 3.524% | -17.089% | -3.868% | -15.292% |
| Baxter International | -1.250% | 15.156% | 21.576% | 19.080% | 39.209% | -44.885% | -65.225% |
| Dentsply Sirona Inc. | -0.250% | 1.845% | 24.865% | -7.465% | 20.855% | -69.306% | -79.177% |
Comments
DexCom (DXCM) had its price target raised by Royal Bank Of Canada from $85.00 to $90.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (DXCM) had its price target raised by Mizuho from $90.00 to $95.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (DXCM) had its "buy" rating reaffirmed by TD Cowen.
Show more
Ratings data for DXCM provided by MarketBeat
News
DexCom Q2 Earnings Call Highlights
Key Points
- Interested in DexCom, Inc.? Here are five stocks we like better.
- DexCom’s Q2 revenue rose 13% year over year to $1.31 billion, driven by continued CGM demand, new-customer starts
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Key Points
- Interested in Teladoc Health, Inc.? Here are five stocks we like better.
- With the GLP-1 agonist market still growing at a rapid pace, companies outside of the pharma industry are
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
Diabetes management is evolving rapidly as the industry innovates to treat the more than 40 million Americans with type 1 or type 2 diabetes. Deciding between two leaders in monitoring and
